

PROFESSIONAL ACTIVITIES**RESEARCH****PAST RESEARCH:**

<u>Grant No.</u>	<u>Grant Title</u>	<u>Years Inclusive</u>	<u>Source</u>
T32-GMO 7281	Medical Scientist Training Grant	1975 to 1982 (Prin. Investigator)	U.S. Public Health Service
5-34355	IHI Fellowship in Immunology “Lymphocyte-endothelial Cell Interactions in Transplantation”	7/88 - 6/90 (Prin. Investigator)	Irvington House Institute for Medical Research
VA-1995	Studies of Hepatotrophic Growth Factors	10/93 - 10/96 (Co-Investigator) (Starzl)	VA
	Effect of Lisoflylline on Bacterial Translocation and Mucosal Barrier	2/97 - 1/98 Consultant (Cicalese)	Cell Therapeutics Inc.
AI40329	Combined Bone Marrow and Organ Transplantation in Humans	4/96 - 3/01 (Prin. Investigator)	NIH
	Evaluation of Interleukin 10 for Therapy of Allograft Rejection	4/95 – 4/99 (Consultant) (Thomson)	Schering- Plough
DK29961	Effects of Orthotopic Liver Transplantation	4/96 - 3/01 (Co-Investigator) (Starzl)	NIH
AA06601	Alcoholic Liver Pathology: Hepatic Cerebral Interaction	4/93 - 3/98 (Consultant) (Tarter)	NIH
	Xenotransplantation Research	3/98-2/01 (Co-PI) (Fung/Starzl)	McCune
	Randomized Open Label, Two	8/98-7/00	Wyeth-Ayerst

	Part Study of Tacrolimus vs Cyclosporine and Sirolimus Followed by Continuous Cyclosporine or Cyclosporine Withdrawal in Liver Transplant Recipients (0468E1-211-US)	(P.I.)	Research
	Autologous LAK Cell Immunotherapy for PTLD	12/96 - 11/01 (Co-Investigator) (Rao)	Cancer Treatment Research Fdn
AI41011	Gene Engineering of Dendritic Cells and Transplantation	5/97 - 4/02 (Consultant) (Thomson)	NIH
DK/AI54232	Modulation of Chimerism for Intestinal Transplantation	4/99-3/04 (Consultant) (Murase)	NIH
DK50680 (Cleveland Clinic)	Multicenter Randomized Trial of DSRS versus TIPS	3/98-8/02 (Co-Investigator (Abu-Elmagd)	NIH
HS09694-03	The Optimal Timing of Liver Transplantation	9/97-8/01 (Co-Investigator) (Roberts)	NIH
	An Open-Label Extension Study of the Safety of Long-Term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients (0468E1-306-US) (PCRN# 1999-0039): Phase II	03/00 – 02/02 (P.I.)	Wyeth-Ayerst
JDFI	Type I Diabetes: Islet	10/99 – 9/04	JDFI

	Transplantation Tolerance	(Co-P.I.)	
	A Phase III, Controlled, Multi-Center, Randomized, Parallel-Group, Single-Blind Study to Compare the Safety and Hemostatic Efficacy of the Fibrin Sealant, Beriplast P, with Standard Care of Thrombin-Smoked Gelfoam in the Treatment of Bleeding from the Hepatic Fossa in Subjects	12/00 – 11/03 (P.I.)	Aventis Behring
	A Phase II, Open-Label, Randomized Study of Conventional Dose Tacrolimus Plus Corticosteroids Versus Reduced Dose Tacrolimus Plus Sirolimus and Corticosteroids in Recipients of Orthotopic Liver Allografts	6/00 – 5/02 (P.I.)	Wyeth-Ayerst Pharm
AI-95830	In Vitro Correlates of Transplant Tolerance in Patients Off Immunosuppression	9/00 – 8/03 (Consultant) (Thomson)	NIH
	A Randomized, Comparative Trial of Prograf (Tacrolimus) in Combination with Sirolimus or Mycophenolate Mofetil after Liver Transplantation	1/01 – 12/03 (P.I.)	Fujisawa Healthcare, Inc
AI40166-06	Multi-Site HIV HIV-Positive Kidney Transplant Study Transplant Study	7/01 – 6/02 (Co-Investigator) (Matas)	NIH

CURRENT RESEARCH

Grant No.	Role in Project
-----------	-----------------

(Funded)	Grant Title	Percentage of Effort	Source
UO1A152748	Solid Organ Transplant in HIV: Multi-Site Study	10/03 – 9/08 CCF PI	NIH
ITN024ST	Phase II multicenter trial to assess the safety and efficacy of Campath-1H and tacrolimus followed by immunosuppression withdrawal in liver transplant.	1/1/2005-12/31/2010 CCF PI	NIH/ITN
ITN030ST	Phase II trial to assess the safety of immunosuppression withdrawal in liver transplant recipients with hepatitis C	8/1/06-9/30/2012 CCF PI	NIH/ITN
ML18423	Roche Cellcept Liver STN	Co-Investigator	Roche
CO168X98	Infliximab (Remicade®) as an Adjunct to Pegylated-Interferon α 2b and Ribavirin in the Treatment of Hepatitis C Virus Infection	Co-PI	Centocor